Vestal Point Capital LP Acquires 750,000 Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS)

Vestal Point Capital LP grew its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS) by 23.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 4,000,000 shares of the biotechnology company’s stock after acquiring an additional 750,000 shares during the period. Astria Therapeutics comprises about 3.3% of Vestal Point Capital LP’s portfolio, making the stock its 8th largest holding. Vestal Point Capital LP owned 7.09% of Astria Therapeutics worth $44,040,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Quest Partners LLC lifted its holdings in shares of Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 3,112 shares during the last quarter. SG Americas Securities LLC acquired a new stake in Astria Therapeutics during the 3rd quarter worth about $155,000. Hsbc Holdings PLC purchased a new stake in Astria Therapeutics during the second quarter valued at about $171,000. Price T Rowe Associates Inc. MD acquired a new position in shares of Astria Therapeutics in the first quarter worth about $200,000. Finally, Intech Investment Management LLC purchased a new position in shares of Astria Therapeutics in the third quarter worth approximately $228,000. 98.98% of the stock is owned by institutional investors.

Astria Therapeutics Price Performance

Shares of NASDAQ:ATXS opened at $10.50 on Friday. The stock has a market capitalization of $592.52 million, a P/E ratio of -5.02 and a beta of 0.71. The business has a 50-day moving average of $11.18 and a two-hundred day moving average of $10.62. Astria Therapeutics, Inc. has a fifty-two week low of $4.50 and a fifty-two week high of $16.90.

Wall Street Analyst Weigh In

Several analysts have recently commented on ATXS shares. Oppenheimer raised their target price on Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Evercore ISI raised Astria Therapeutics to a “strong-buy” rating in a research note on Wednesday, August 14th. Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a research note on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, Astria Therapeutics presently has an average rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.